QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
QuidelOrtho Corp
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 7, 2026
$12.76−0.15 (-1.16%)
Close on Oct 19, 2026
- Market cap
- $871.51M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
46.7%−35.0 pts over 5 years
Operating margin
-33.7%−97.5 pts over 5 years
Net margin
-41.5%−90.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -1.9% | -5.8% | +10.4% | – | |
| Gross profit | -1.0% | -13.0% | -1.2% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 85.6% | -46.1% | |
| Return on assets | – | – | -18.6% | |
| Current ratio | – | – | 1.50 | |
| Debt to equity | – | – | 1.38 | |
| Net debt to EBITDA | – | – | -5.20× | |
| Interest coverage | – | – | -5.2× | |
| Inventory turnover | – | – | 2.6× | |
| Capex to revenue | – | 3.9% | 6.9% | |
| Diluted shares | – | 44M | 68M |
Where the cash went
Fiscal 2021 to 2025, five years combined
QuidelOrtho generated $2.16B from operations and spent $1.21B on capital expenditure, dividends and share buybacks. 85% of that went back into the business.
Generated
$2.16B
Used
$1.21B
Capital expenditure$1.03B85%Dividends$00%Share buybacks$185.00M15%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-41.5%
×Asset turnover0.45×
×Equity multiplier2.49×
=Return on equity, FY2025-46.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -41.5% | 0.45× | 2.49× | -46.1% |
| FY2024 | -73.7% | 0.37× | 1.88× | -51.4% |
| FY2023 | -0.3% | 0.34× | 1.75× | -0.2% |
| FY2022 | 16.8% | 0.58× | 1.64× | 16.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$1.13B
- Cash generatingOperating cash flow above zero$105.20M
- Return on assets improvedROA up on the prior year-24.0% → -17.6%
- Earnings backed by cashOperating cash flow above net income$105.20M vs -$1.13B
- Less leverageLong-term debt to assets fell33.3% → 42.8%
- Better liquidityCurrent ratio rose1.22 → 1.50
- No dilutionShare count did not rise67M → 68M
- Gross margin improvedGross margin up on the prior year46.23% → 46.67%
- More efficientAsset turnover rose0.32 → 0.43